TransCode Therapeutics, Inc. (RNAZ) shares surged 20.70 percent, rising $2.53 to $14.75 on Wednesday, after announcing the acquisition of Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage melanoma vaccine candidate. The company also secured a $25 million investment from CK Life Sciences to fund its Phase 2 trial of lead microRNA therapy TTX-MC138.
The stock is currently trading at $14.23, compared with a previous close of $12.22 on the Nasdaq. Shares opened at $18.91 and have traded between $13.18 and $20.99 so far today, with trading volume reaching 7.1 million shares, above the average of 88,000.
Over the past 52 weeks, TransCode shares have ranged between $6.15 and $739.20.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.